ClinicalTrials.gg
Not yet recruitingNCT06751485Updated Dec 31, 2024

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

A Phase 3 interventional study of JSKN003 and Doxorubicin in Ovarian Cancer, Primary Peritoneal and Fallopian Tube Cancers, sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-31.

Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd (part of Alphamab Oncology) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN003 versus investigator's choice of chemotherapy in patients with platinum-resistant, relapsed epithelial Ovarian, primary peritoneal, or fallopian tube cancer.

02

Conditions studied

  • Ovarian Cancer
  • Primary Peritoneal
  • Fallopian Tube Cancers

Keywords

  • JSKN003-306
03

In context

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

This study's planned enrollment of 430 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.

Browse Ovarian Neoplasms studies →

Lead sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd is the lead sponsor of 38 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary participation and written .
  • ≥18 years;
  • confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
  • Confirmed platinum-resistant relapse.
  • According to 1.1 criteria, there must be at least one in the baseline.
  • Expected survival of more than 3 months.
  • performance status score of 0 or 1.
  • Adequate organ function.
  • Capable and willing to comply with the study protocol, treatment plan, laboratory tests, and other related study procedures.

Exclusion criteria

Exclusion Criteria:

  • Primary platinum- disease.
  • Active central nervous system .
  • Uncontrolled pleural effusion.
  • Previous treatment with topoisomerase I inhibitor ADCs.
  • Other malignant tumors within 5 years.
  • Interstitial pneumonia/lung disease requiring systemic or suspected interstitial pneumonia/lung disease.
  • Uncontrolled comorbidities.
  • Toxicity from previous anti-cancer treatments not recovered to Grade ≤1.
  • History of allogeneic bone marrow or organ transplantation.
  • Allergic reactions or to antibody drugs.
  • Conditions affecting study drug treatment safety or compliance, including psychiatric disorders, alcohol abuse, or drug abuse.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
430 participants (estimated)

Study arms

  • Experimental
    Experimental: Treatment group 1:JSKN003

    Drug: JSKN003 JSKN003 dose 1

    Drug: JSKN003

  • Active comparator
    Active Comparator: Treatment group 2: Investigator's choice of chemotherapy

    Drug: Doxorubicin Doxorubicin dose 2 Drug: Paclitaxel Paclitaxel dose 3 Drug: Topotecan Topotecan dose 4

    Drug: Doxorubicin · Drug: Paclitaxel · Drug: Topotecan

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) assessed by Blinded Independent Review Committee (BIRC) as per RECIST 1.1

    PFS was defined as the time from randomization until the date of progressive disease or death, whichever occurred first

    Time frame: Up to approximately 22 months

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of first dose until the date of death from any cause

    Time frame: Up to approximately 22 months

  2. Overall Response Rate (ORR) evaluated by BIRC as per RECIST 1.1

    ORR was defined as the proportion of subjects achieving Complete Response (CR) or Partial Response (PR)

    Time frame: Up to approximately 22 months

  3. Duration of Response (DoR) evaluated by BIRC as per RECIST 1.1

    DOR was defined as the time from CR/PR to PD or death from any cause, whichever occurs first

    Time frame: Up to approximately 22 months

  4. Disease Control Rate (DCR) evaluated by BIRC as per RECIST 1.1

    DCR was defined as the proportion of subjects whose best overall response is CR, PR, or Stable Disease (SD)

    Time frame: Up to approximately 22 months

  5. PFS evaluated by the Investigator as per RECIST 1.1

    PFS was defined as the time from randomization until the date of progressive disease or death, whichever occurred first

    Time frame: Up to approximately 22 months

  6. ORR evaluated by the Investigator as per RECIST 1.1

    ORR was defined as the proportion of subjects achieving Complete Response (CR) or Partial Response (PR)

    Time frame: Up to approximately 22 months

  7. DoR evaluated by the Investigator as per RECIST 1.1

    DOR was defined as the time from CR/PR to PD or death from any cause, whichever occurs first

    Time frame: Up to approximately 22 months

  8. DCR evaluated by the Investigator as per RECIST 1.1

    DCR was defined as the proportion of subjects whose best overall response is CR, PR, or Stable Disease (SD)

    Time frame: Up to approximately 22 months

  9. CA-125 Response Rate assessed by the Gynaecologic Cancer Intergroup (GCIG) criteria

    CA-125 Response Rate was assessed according to the GCIG criteria

    Time frame: Up to approximately 22 months

  10. Number and Severity of Treatment-emergent Adverse Events (TEAEs)

    The incidence and severity of TEAEs and TRAEs (Treatment-related Adverse Events, graded according to NCI CTCAE 5.0), Serious AEs (SAEs), laboratory tests, etc.

    Time frame: Up to approximately 22 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Dec 2026, 23 months later.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 23 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2024
First posted
Dec 30, 2024
StartEst.
Jan 15, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2027
Last update
Dec 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06751485
Responsible party
Sponsor
First posted
Dec 30, 2024
Start date
Jan 15, 2025 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Dec 31, 2024

Study contacts

Lingying Wu, Doctor
Contact
wulingying@csco.org.cn
8610-87788495

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anbenitamab repodatecan

Start the discussion